Evidence map›Paper›PMID 33423239›Full record

ArticleHepatology international2021

Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan.

Fu-Shun Yen, James Cheng-Chung Wei, Hei-Tung Yip, Chii-Min Hwu, Ming-Chih Hou, Chih-Cheng Hsu

Abstract read
PubMed Publisher
In one paragraph

Article in Hepatology international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. [Expert consensus on the management of diabetes mellitus in patients with liver cirrhosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022
    Article
  11. Review
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Fu-Shun YenDr. Yen's Clinic, No. 15, Shanying Road, Gueishan District, Taoyuan, 33354, Taiwan.
James Cheng-Chung WeiDivision of Allergy, Immunology and Rheumatology Chung, Shan Medical University Hospital, No. 110, Sec. 1, Jianguo N. Rd., South District, Taichung City, 40201, Taiwan.
Hei-Tung YipManagement Office for Health Data, China Medical University Hospital, 3F., No. 373-2, Jianxing Road, Taichung, 40459, Taiwan.
Chii-Min HwuFaculty of Medicine, National Yang-Ming University School of Medicine, No. 155, Sec.2, Linong Street, Taipei, 11221, Taiwan.
Ming-Chih HouFaculty of Medicine, National Yang-Ming University School of Medicine, No. 155, Sec.2, Linong Street, Taipei, 11221, Taiwan. mchou@vghtpe.gov.tw.
Chih-Cheng HsuInstitute of Population Health Sciences, National Health Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli County, 35053, Taiwan. cch@nhri.edu.tw.
China Medical University · TWChung Shan Medical University Hospital · TWNational Health Research Institutes · TWNational Yang Ming Chiao Tung University · TWTaipei Veterans General Hospital · TW

Funding

Ministry of Science and Technology Clinical Trial Consortium for Stroke MOST 108-2321-B-039-003-Taiwan Ministry of Health and Welfare Clinical Trial Center MOHW109-TDU-B-212-114004
6 · The paper itself

Abstract

background/purposeManagement of type 2 diabetes mellitus (T2DM) in patients with liver cirrhosis is complex and suboptimal, but no clinical trial has adequately investigated antidiabetic drug use for such patients. We evaluate the risk of mortality, cardiovascular events, and hepatic outcomes between dipeptidyl peptidase-4 (DPP-4) inhibitor users and nonusers in patients with type 2 diabetes mellitus (T2DM) and cirrhosis.

methodsWe selected 2828 paired propensity score matched DPP-4 inhibitor users and nonusers from a cohort of T2DM with compensated liver cirrhosis between January 1, 2007, and December 31, 2012. Cox proportional hazards models were used to assess the risk of main outcomes for DPP-4 inhibitor users.

resultsThe incidence rate of decompensated cirrhosis during follow-up was 2.20 and 1.53 per 100 patient-years (adjusted hazard ratio [aHR] 1.35, 95% confidence interval [CI] 1.03-1.77) for DPP-4 inhibitor users and nonusers, respectively. The aHRs (95% CI) of variceal bleeding and hepatic failure were 1.67 (1.11-2.52) and 1.35 (1.02-1.79), respectively, for DPP-4 inhibitor users over nonusers. The risk of all-cause mortality, hepatocellular carcinoma, and major cardiovascular events between DPP-4 inhibitor users and nonusers were not statistically different.

conclusionsThis study found that DPP-4 inhibitor users were associated with higher risks of decompensated cirrhosis and hepatic failure than did nonusers among patients with T2DM and compensated liver cirrhosis. We must continue to search for appropriate antidiabetic drugs for patients with liver cirrhosis.

Indexed as

Liver CirrhosisDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsDipeptidyl-Peptidases and Tripeptidyl-PeptidasesEsophageal and Gastric VaricesGastrointestinal HemorrhageHumansHypoglycemic AgentsRetrospective StudiesTaiwanDipeptidyl-Peptidase IV InhibitorsDipeptidyl-Peptidases and Tripeptidyl-PeptidasesHypoglycemic AgentsCardiovascular eventsCompensated liver cirrhosisDecompensated cirrhosisHepatic failureHepatic outcomesHepatocellular carcinomaManagementMortalityType 2 diabetes mellitusVariceal bleeding

Identifiers

PMID33423239
OpenAlexW3120990251

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.